Analysis of the MMP-dependent and independent functions of tissue inhibitor of metalloproteinase-2 on the invasiveness of breast cancer cells

[1]  L. Walsh,et al.  Analysis of the MMP-dependent and independent functions of tissue inhibitor of metalloproteinase-2 on the invasiveness of breast cancer cells , 2012, Journal of Cell Communication and Signaling.

[2]  R. Fridman,et al.  Assessment of gelatinases (MMP-2 and MMP-9) by gelatin zymography. , 2012, Methods in molecular biology.

[3]  K. Bhoola,et al.  Activation of kinin B1 receptor increases the release of metalloproteases-2 and -9 from both estrogen-sensitive and -insensitive breast cancer cells. , 2011, Cancer letters.

[4]  N. Gooderham,et al.  The cooked meat-derived mammary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine promotes invasive behaviour of breast cancer cells. , 2011, Toxicology.

[5]  V. Lesauskaitė,et al.  Matrix metalloproteinase-9 is a prognostic marker to predict survival of patients who underwent surgery due to rectal carcinoma. , 2011, The Tohoku journal of experimental medicine.

[6]  L. Walsh,et al.  IGF-1 increases invasive potential of MCF 7 breast cancer cells and induces activation of latent TGF-β1 resulting in epithelial to mesenchymal transition , 2011, Cell Communication and Signaling.

[7]  W. Parks,et al.  Mouse models of MMP and TIMP function. , 2010, Methods in molecular biology.

[8]  J. Pringle,et al.  Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms , 2009, Breast Cancer Research.

[9]  M. Sogayar,et al.  Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential , 2009, BMC Cancer.

[10]  A. Hölscher,et al.  Clinicopathological significance of MMP-2 and its specific inhibitor TIMP-2 in gastric cancer. , 2008, Histology and histopathology.

[11]  W. Stetler-Stevenson.  The tumor microenvironment: regulation by MMP-independent effects of tissue inhibitor of metalloproteinases-2 , 2008, Cancer and Metastasis Reviews.

[12]  M. Noda,et al.  Recklessness as a hallmark of aggressive cancer , 2007, Cancer science.

[13]  L. Walsh,et al.  Membrane Type-1 Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases-2 RNA Levels Mimic Each Other during Xenopus laevis Metamorphosis , 2007, PloS one.

[14]  W. Parks,et al.  Control of matrix metalloproteinase catalytic activity. , 2007, Matrix biology : journal of the International Society for Matrix Biology.

[15]  S. Nakajima,et al.  Effects of the components of hormone therapy on matrix metalloproteinases in breast-cancer cells: an in vitro study. , 2007, Fertility and sterility.

[16]  M. Ratajczak,et al.  Enhancing effect of platelet‐derived microvesicles on the invasive potential of breast cancer cells , 2006, Transfusion.

[17]  L. Meng,et al.  Enhanced in vitro invasiveness of ovarian cancer cells through up-regulation of VEGF and induction of MMP-2. , 2006, Oncology reports.

[18]  H. Nielsen,et al.  Quantification of Tissue Inhibitor of Metalloproteinases 2 in Plasma from Healthy Donors and Cancer Patients , 2005, Scandinavian journal of immunology.

[19]  W. Stetler-Stevenson,et al.  TIMP-2: an endogenous inhibitor of angiogenesis. , 2005, Trends in molecular medicine.

[20]  W. Stetler-Stevenson,et al.  Tissue Inhibitors of Metalloproteinase 2 Inhibits Endothelial Cell Migration through Increased Expression of RECK , 2004, Cancer Research.

[21]  Z. Werb,et al.  Regulation of matrix biology by matrix metalloproteinases. , 2004, Current opinion in cell biology.

[22]  B. Haye,et al.  TIMPs as multifacial proteins. , 2004, Critical reviews in oncology/hematology.

[23]  V. Gouyer,et al.  Specific expression of matrix metalloproteinases 1, 3, 9 and 13 associated with invasiveness of breast cancer cells in vitro , 2004, Clinical & Experimental Metastasis.

[24]  M. Seiki,et al.  MT-MMPs play pivotal roles in cancer dissemination , 2004, Clinical & Experimental Metastasis.

[25]  J. Shaw,et al.  Primary breast myoepithelial cells exert an invasion‐suppressor effect on breast cancer cells via paracrine down‐regulation of MMP expression in fibroblasts and tumour cells , 2003, The Journal of pathology.

[26]  Carine Munaut,et al.  MMP‐2 and MMP‐9 synergize in promoting choroidal neovascularization , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  P. Wingfield,et al.  TIMP-2 Mediated Inhibition of Angiogenesis An MMP-Independent Mechanism , 2003, Cell.

[28]  Edgar D Staren,et al.  Matrix metalloproteinase expression in breast cancer. , 2003, The Journal of surgical research.

[29]  A. Strongin,et al.  Gelatin Zymography and Substrate Cleavage Assays of Matrix Metalloproteinase-2 in Breast Carcinoma Cells Overexpressing Membrane Type-1 Matrix Metalloproteinase , 2002, Laboratory Investigation.

[30]  L. Coussens,et al.  RECKing MMP function: implications for cancer development. , 2002, Trends in cell biology.

[31]  A. Dove.  MMP inhibitors: Glimmers of hope amidst clinical failures , 2002, Nature Medicine.

[32]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[33]  P. Wingfield,et al.  Biophysical and Functional Characterization of Full-length, Recombinant Human Tissue Inhibitor of Metalloproteinases-2 (TIMP-2) Produced in Escherichia coli , 1999, The Journal of Biological Chemistry.

[34]  Y. DeClerck,et al.  Tissue Inhibitor of Metalloproteinase-2 (TIMP-2) Binds to the Catalytic Domain of the Cell Surface Receptor, Membrane Type 1-Matrix Metalloproteinase 1 (MT1-MMP)* , 1998, The Journal of Biological Chemistry.